News | March 03, 2022
IHub-Data and IIIT-Hyderabad offer course on drug discovery
12-week certificate course commences on March 10th 2022
12-week certificate course commences on March 10th 2022
Nirsevimab is the first investigational long-acting antibody designed to protect all infants for the respiratory syncytial virus season with a single dose
Optimized for pharma/biopharma to deliver a deeper understanding of cellular function
The FDA grants ODD status to medicines and potential new medicines intended for the treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the US
Molflu is expected to be available from early next week in pharmacies throughout the country with a particular focus on states with a high caseload of Covid-19.
Molnupiravir is an investigational oral antiviral medicine, for the treatment of mild-to-moderate COVID-19 in at risk adults
Sputnik Light has been authorised in more than 15 countries with the registration process ongoing in a further 30 countries
This capability programme aims to upskill 5000 nurses across the country in the next year by converting the current modules into an e-learning one
The global wellness market is valued at more than US $ 1.5 trillion, with annual growth of 5-10 per cent
As part of this strategic partnership, LTI with its digital, technical and life sciences domain capabilities, will help accelerate joint go-to-market pursuits and faster deployment for Clinpal Adopters
Subscribe To Our Newsletter & Stay Updated
